MAZE
Maze Therapeutics Inc.

56
Mkt Cap
$2.01B
Volume
245,612.00
52W High
$43.29
52W Low
$6.71
PE Ratio
-18.50
MAZE Fundamentals
Price
$41.71
Prev Close
$42.60
Open
$42.07
50D MA
$31.74
Beta
1.07
Avg. Volume
427,583.79
EPS (Annual)
$0.0778
P/B
5.28
Rev/Employee
$1.34M
Loading...
Loading...
News
all
press releases
Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week High - Time to Buy?
Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year High - Still a Buy...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
MAZE Crosses Above Average Analyst Target
In recent trading, shares of Maze Therapeutics Inc (Symbol: MAZE) have crossed above the average analyst 12-month target price of $40.14, changing hands for $41.49/share. When a stock reaches the...
Nasdaq News: Markets·2d ago
News Placeholder
Virtus Investment Advisers LLC Invests $85,000 in Maze Therapeutics, Inc. $MAZE
Virtus Investment Advisers LLC bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the second quarter, according to its most recent 13F filing with the Securities...
MarketBeat·4d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week High - Time to Buy?
Maze Therapeutics (NASDAQ:MAZE) Reaches New 12-Month High - Here's Why...
MarketBeat·11d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 8.4% - Should You Buy?
Maze Therapeutics (NASDAQ:MAZE) Trading Up 8.4% - Should You Buy...
MarketBeat·16d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at Raymond James Financial
Raymond James Financial began coverage on shares of Maze Therapeutics in a research note on Thursday. They set an "outperform" rating on the stock...
MarketBeat·20d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Sees Strong Trading Volume - Here's Why
Maze Therapeutics (NASDAQ:MAZE) Sees Strong Trading Volume - What's Next...
MarketBeat·21d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Given New $36.00 Price Target at Wedbush
Wedbush upped their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the company an "outperform" rating in a research note on Friday...
MarketBeat·28d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Releases Earnings Results, Beats Expectations By $0.08 EPS
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus...
MarketBeat·29d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 9.6% - Here's What Happened
Maze Therapeutics (NASDAQ:MAZE) Trading Down 9.6% - Here's What Happened...
MarketBeat·1mo ago

Latest MAZE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.